The Effect of Dexmedetomidine on the Prognosis of Mechanically Ventilated Patients with Sepsis: A Meta-Analysis of Randomized Controlled Trials
Abstract
Background: Dexmedetomidine (Dex), as a new and highly selective α2 adrenergic receptor agonist, has been widely used in mechanically ventilated patients. In the present study, we used meta-analysis to study the effect of Dex on the prognosis of mechanically ventilated patients with sepsis.
Methods: We searched PubMed, Cochrane clinical trial, EMBASE, Web of Science, and Chinese biomedical literature database to analyze relevant literature published from January 2000 to January 2021. We conducted the quality evaluation and data extraction for studies that met the inclusion criteria. RevMan 5.3 software was used to perform a meta-analysis of the 28-day mortality, hospital mortality, the length of ICU stay, and other adverse indicators.
Results: Ten randomized controlled trials (RCTs) that met the inclusion criteria were finally included, including 9 RCTs in English and one in Chinese, with a total of 892 patients. Our meta-analysis results found that in mechanically ventilated patients with sepsis, Dex could significantly reduce the length of ICU stay (P=0.02), but did not reduce the patients' 28-day mortality (P=0.06), hospital mortality (P=0.17) and ventilator-free days (P=0.33). Furthermore, our meta-analysis results also found that Dex had no significant effect on the respiratory rate (P=0.53), heart rate (P=0.02), mean arterial pressure (P=0.63), the level of creatinine (P=0.82) and continuous renal replacement therapy (P=0.39) in mechanically ventilated patients with sepsis.
Conclusion: In mechanically ventilated patients with sepsis, Dex can reduce the length of ICU stay, but which cannot reduce the 28-day mortality, hospital mortality, and ventilator-free days.
2. Chandrasekhar R, Hughes CG, Pun BT, et al (2020). Statistical analysis plan for the Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients with Acute Respiratory Failure trial. Crit Care Resusc, 22(1):63-71.
3. Ohta Y, Miyamoto K, Kawazoe Y, et al (2020). Effect of dexmedetomidine on inflammation in patients with sepsis re-quiring mechanical ventilation: a sub-analysis of a multicenter randomized clin-ical trial. Crit Care, 24(1):493.
4. Yamamoto T, Mizobata Y, Kawazoe Y, et al (2020). Incidence, risk factors, and out-comes for sepsis-associated delirium in patients with mechanical ventilation: A sub-analysis of a multicenter randomized controlled trial. J Crit Care, 56:140-144.
5. Morelli A, Sanfilippo F, Arnemann P, et al (2019). The Effect of Propofol and Dexmedetomidine Sedation on Norepi-nephrine Requirements in Septic Shock Patients: A Crossover Trial. Crit Care Med, 47(2):e89-e95.
6. Mohamed H, Hosny H, Tawadros Md P, et al (2020). Effect of Dexmedetomidine In-fusion on Sublingual Microcirculation in Patients Undergoing On-Pump Coronary Artery Bypass Graft Surgery: A Prospec-tive Randomized Trial. J Cardiothorac Vasc Anesth, 33(2):334-340.
7. Deng Y, Tan F, Gan X, et al (2018). Periop-erative application of dexmedetomidine for postoperative systemic inflammatory response syndrome in patients undergo-ing percutaneous nephrolithotomy litho-tripsy: results of a randomised controlled trial. BMJ Open, 8(11):e019008.
8. Yang CL, Tsai PS, Huang CJ (2008). Effects of dexmedetomidine on regulating pul-monary inflammation in a rat model of ventilator-induced lung injury. Acta Anaes-thesiol Taiwan, 46(4):151-159.
9. Memiş D, Hekimoğlu S, Vatan I, et al (2007). Effects of midazolam and dexme-detomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth, 98(4):550-552.
10. Kadoi Y, Saito S, Kawauchi C, et al (2008). Comparative effects of propofol vs dexmedetomidine on cerebrovascular carbon dioxide reactivity in patients with septic shock. Br J Anaesth, 100(2):224-229.
11. Tasdogan M, Memis D, Sut N, et al (2009). Results of a pilot study on the effects of propofol and dexmedetomidine on in-flammatory responses and in-traabdominal pressure in severe sepsis. J Clin Anesth, 21(6):394-400.
12. Pandharipande PP, Sanders RD, Girard TD, et al (2010). Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care, 14(2):R38.
13. Guo F, Wang Q, Yan CY, et al (2016). Clini-cal application of different sedation regi-men in patients with septic shock. Zhong-hua Yi Xue Za Zhi, 96(22):1758-1761. [arti-cle in Chinese]
14. Kawazoe Y, Miyamoto K, Morimoto T, et al (2017). Effect of Dexmedetomidine on Mortality and Ventilator-Free Days in Pa-tients Requiring Mechanical Ventilation with Sepsis: A Randomized Clinical Trial. JAMA, 317(13):1321-1328.
15. Miyamoto K, Nakashima T, Shima N, et al (2018). Effect of Dexmedetomidine on Lactate Clearance in Patients With Septic Shock: A Subanalysis of a Multicenter Randomized Controlled Trial. Shock, 50(2):162-166.
16. Liu J, Shi K, Hong J, et al (2020). Dexme-detomidine protects against acute kidney injury in patients with septic shock. Ann Palliat Med, 9(2):224-230.
17. Cioccari L, Luethi N, Bailey M, et al (2020). The effect of dexmedetomidine on vaso-pressor requirements in patients with septic shock: a subgroup analysis of the Sedation Practice in Intensive Care Evalu-ation [SPICE III] Trial. Crit Care, 24(1):441.
18. Nakashima T, Miyamoto K, Shima N, et al (2020). Dexmedetomidine improved re-nal function in patients with severe sep-sis: an exploratory analysis of a random-ized controlled trial. J Intensive Care, 8:1.
19. Napolitano LM (2018). Sepsis 2018: Defini-tions and Guideline Changes. Surg Infect (Larchmt), 19(2):117-125.
20. Fan H, Zhao Y, Sun M, et al (2018). Urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, N-acetyl-β-D-glucosaminidase levels and mortality risk in septic patients with acute kidney injury. Arch Med Sci, 14(6):1381-1386.
21. Fan H, Zhao Y, Chen GD, et al (2019). Health insurance status and risk factors of mortality in patients with septic acute kidney injury in Ningbo, China. J Int Med Res, 47(1):370-376.
22. Rello J, Valenzuela-Sánchez F, Ruiz-Rodriguez M, et al (2017). Sepsis: A Re-view of Advances in Management. Adv Ther, 34(11):2393-2411.
23. Taniguchi T, Kurita A, Kobayashi K, et al (2008). Dose- and time-related effects of dexmedetomidine on mortality and in-flammatory responses to endotoxin-induced shock in rats. J Anesth, 22(3):221-228.
24. Riker RR, Shehabi Y, Bokesch PM, et al (2009). Dexmedetomidine vs midazolam for sedation of critically ill patients: a ran-domized trial. JAMA, 301(5):489-499.
25. Esposito S, De Simone G, Boccia G, et al (2017). Sepsis and septic shock: New def-initions, new diagnostic and therapeutic approaches. J Glob Antimicrob Resist, 10:204-212.
26. Balkanay OO, Goksedef D, Omeroglu SN, et al (2015). The dose-related effects of dexmedetomidine on renal functions and serum neutrophil gelatinase-associated lipocalin values after coronary artery by-pass grafting: a randomized, triple-blind, placebo-controlled study. Interact Cardio-vasc Thorac Surg, 20(2):209-214.
27. Malbrain ML, De Laet IE, De Waele JJ, et al (2013). Intra-abdominal hypertension: definitions, monitoring, interpretation and management. Best Pract Res Clin Anaes-thesiol, 27(2):249-270.
28. Zhang WQ, Xu P, Zhan XH, et al (2019). Efficacy of dexmedetomidine for treat-ment of patients with sepsis: A meta-analysis of randomized controlled trials. Medicine (Baltimore), 98(18):e15469.
| Files | ||
| Issue | Vol 51 No 10 (2022) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/ijph.v51i10.10976 | |
| Keywords | ||
| Dexmedetomidine Sepsis Mechanical ventilation Mortality Meta-analysis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
